Homocysteinemia as a risk factor for atherosclerosis: A review

Cardiovascular Pathology

Volumn 6, Issue 1, 1997, Pages 1-9

  Nehler, Mark R ^a   Taylor Jr , Lloyd M ^a   Porter, John M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY RISK; HUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0031033141     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(96)00064-6     Document Type: Review

References (97)

1. Gordon T, Garcia-Palmieri MR, Dagan A, et al. Differences in coronary heart disease in Framingham, Honolulu, and Puerto Rico. J Chronic Dis 1974;27:329-344.
2. McCully KS. Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. Am J Med Sci 1990;299: 217-221.
3. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation of S-adenosylmethionine of the remethylation and transulfuration of homocysteine. Am J Clin Nutr 1992;55:131-138.
4. Carson NA, Neill DW. Metabolic abnormalities detected in s survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962;31:653-676.
5. Gerritsent T, Vaughn JG, Waisman HA. The identification of homocysteine in the urine. Biochem Biophys Res Commun 1962;9:493-496.
6. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
7. Mudd SH, Finkelstein JD, Irrevere F, Laster L. Homocystinuria: an enzymatic defect. Science 1964;143:1443-1445.
8. Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, Shih VE. Molecular basis of cystathionine β-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum Mol Genet 1993;2:1857-1860.
9. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. AmJ Pathol 1969;56:111-128.
10. Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 1972;46:905-912.
11. Harker LA, Slicter SF, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-543.
12. Harker LA, Ross R, Slichter SF, Scott CR. Homocystine-induced arteriosclerosis. J Clin Invest 1976;16:731-741.
13. Hladovec J. Experimental homocystinemia, endothelial lesions and thrombosis. Blood Vessels 1979;16:202-205.
14. Perry TL, Hansen S, MacDougall L, Warrington PD. Sulfur containing amino acids in the plasma and urine of homocystinurics. Clin Chim Acta 1967;15:409-420.
15. Malloy MH, Rassin DK, Gaull GE. Plasma cysteine in homocysteinemia. Am J Clin Nutr 1981;34:2619-2621.
16. Schneider JA, Bradley KH, Seegmiller JE. Identification and measurement of cysteine-homocysteine mixed disulfide in plasma. J Lab Clin Med 1968;71:122-125.
17. Gupta VJ, Wilcken DE. The detection of cysteine-homocysteine mixed disulfide in plasma of normal fasting man. Eur J Clin Invest 1978;8:205-207.
18. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976;57: 1079-1082.
19. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715.
20. Taylor LM Jr, Porter JM. Elevated plasma homocysteine as a risk factor for atherosclerosis. Semin Vase Surg 1993;6:36-45.
21. Kang SS, Wong PW, Cook HY, et al. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 1986; 77:1482-1486.
22. Malinow MR, Kang SS, Taylor LM Jr, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
23. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem 1988;168:374-379.
24. Brattstrom LE. Heterozygosity for homocystinuria in premature arterial disease. N Engl J Med 1986;314:849-850.
25. Cronwell PE, Morgan SL, Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr 1993;617:136-139.
26. Andersson A, Isaksson A, Brattstrom L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993;39:1590-1597.
27. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993;39:263-271.
28. Stabler SP, Marcell PD, Podell ER, Allen RH. Quantification of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem 1987;162:185-196.
29. Refsum H, Heiland S, Ueland PM. Radioenzymic determinations of homocysteine in plasma and urine. Clin Chem 1985;31:624-628.
30. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-881.
31. Evroski J, Callaghan M, Cole DE. Determination of homocysteine by HPLC with pulsed integrated amperometry. Clin Chem 1995;41:757-759.
32. Jacobsen DW, Gatautis VJ, Green R. Determination of plasma homocysteine by high-performance liquid chromatography with fluorescence detection. Anal Biochem 1989;178:208-214.
33. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993;103:149-157.
34. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B. Hyperhomocysteinemia in stroke: prevalence, cause, and relationship to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-221.
35. Reed T, Malinow MR, Christian JC, Upson B. Estimates of heritability of plasma homocyst(e)ine levels in aging adult male twins. Clin Genetics 1991;39:425-428.
36. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-462.
37. 6: relationship to atherosclerosis. J Nutr 1983;133:2022-2033.
38. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine B-synthase deficiency. Metabolism 1988;37:175-178.
39. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cobalamin. Eur J Clin Invest 1979;9:301-307.
40. Mason JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197-203.
41. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
42. Wilcken DE, Gupta VJ. Sulfur containing amino acids in chronic renal failure with particular reference to homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301-307.
43. Kang SS, Wong PW, Bidani A, Milanez S. Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis. Clin Sci 1983;65:335-336.
44. Chauveau P, Chadefaux B, Coude M, et al. Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 1992;18:196-198.
45. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-234.
46. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, deGarmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-576.
47. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vase Surg 1991;13:128-136.
48. Parfrey PS, Harnett JD. Long term cardiac morbidity during dialysis therapy. Adv Nephrol 1994;23:311.
49. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24: 733-736.
50. Kang SS, Wong PW, Zhou J, Cook HY. Preliminary report: total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 1986;35:899-891.
51. Andersson A, Hultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30: 377-379.
52. Malinow MR, Levenson J, Giral P, et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995;114:175-183.
53. Levenson J, Malinow MR, Giral PH, Razavian M, Simon A. Increased plasma homocyst(e)ine levels in human hypertension. J Hypertens 1994;12:S74.
54. Kang SS, Wong PW, Cook HY, et al. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-1486.
55. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-233.
56. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-715.
57. Malinow MR, Sexton G, Averbach M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Cor Art Dis 1990;1:215-220.
58. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inemia: an independent risk factor for claudication. J Int Med 1992;231:273-279.
59. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arteriosclerosis Thromb 1991;11:1129-1136.
60. Araki A, Sako Y, Fukushima Y, et al. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive patients. Atherosclerosis 1989;79:139-146.
61. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-561.
62. Lewis CA, Pancharunitti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann NY Acad Sci 1992; 669: 360-362.
63. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
64. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-298.
65. Andersson A, Brattstrom L, Israelsson B, et al. Plasma homocyst(e)ine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992;22:79-87.
66. Kang SS, Wong PW, Otto Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia from compound heterozygosity of methylene-tetrahydrofolate reductase mutations. Am J Hum Genet 1991;48: 546-561.
67. Mudd SH, Levy HL, Skovy F. Disorders of transsulfuration. In: Scriver CR, Beaudet Al, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw Hill, 1995; 1279-1328.
68. Sartorio R, Carrozzo R, Corbo L, Andria G. Protein-bound plasma homocyst(e)ine and identification of heterozygotes for cystathionine synthase deficiency. J Inherited Metab Dis 1986;9:25-29.
69. Kang SS, Wong PW, Susmano A, Sora SA, Norius M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-545.
70. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-113.
71. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the atherosclerosis risk in communities study. Circulation 1993;87:1107-1113.
72. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and the risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
73. Lee RW, Nehler MR, Moneta GL, Taylor LM Jr, Porter JM. Serum homocysteine and atherosclerosis progression: methods, patient characteristics, and progress (manuscript in progress).
74. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-128.
75. McCully KS, Olszewski AJ, Veseridis MP. Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thilactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis 1990; 83:197-206.
76. McCully KS, Homocysteine theory of arteriosclerosis: development and current status. In: Gotto AM Jr, Paoletti R, eds. Atherosclerosis Reviews. New York: Raven Press, 1983;11:157-247.
77. Ueland PM, Refsum H. Plasma homocysteine: a risk factor for vascular disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
78. Wang J, Dudman NP, Wilcken DE, Lynch JF. Homocysteine catabolism: levels of three enzymes in cultured human vascular endothelium and their relevance to vascular disease. Atherosclerosis 1992;97:97-106.
79. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 1993;108:920-926.
80. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-1376.
81. Clarke R, Naughten E, Cahalane S, et al. The role of free radicals as mediators of endothelial cell injury in hyperhomocysteinemia UMS 1992;161:561-564.
82. Blom HJ, Engelsen DP, Boers GH, et al. Lipid peroxidation in homocysteinaemia. J Inherited Metab Dis 1992;15:419-422.
83. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
84. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-2936.
85. Lentz SR, Sadler JE, Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993;81:683-689.
86. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982;16:490-493.
87. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig: captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161-1174.
88. Brattstrom LE, Israelsson B, Jeppson JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-221.
89. Amadottir M, Brattstrom L, Simonsen O, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993;40:236-240.
90. 6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inherited Metab Dis 1994;17:159-162.
91. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria -the effects of betaine in the treatment of patients not responsive to py-ridoxine. N Engl J Med 1983;309:448-453.
92. Stabler SP, Marcell PD, Podell ER, et al. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectroscopy. J Clin Invest 1988;81:466-474.
93. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cobalamin. Eur J Haematol 1993;51:25-30.
94. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346: 85-89.
95. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vase Surg 1994;20:933-940.
96. Franken DG, Boers GH, Blom HJ, Trijbels FJ, Kloppenborg PW. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arteriosclerosis Thromb 1994;14:465-470.
97. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.